In experimental laboratory models of mitochondrial complex I deficiency, the therapeutic compound bezafibrate partially alleviated mitochondrial dysfunction in cells and significantly mitigated disease symptoms in mice, according to an investigation published in the Orphanet Journal of Rare Diseases. The research examined pathological mechanisms underlying Leigh syndrome, a severe and devastating mitochondrial encephalopathy caused by impaired oxidative phosphorylation and consequent bioenergetic failure across affected physiological systems. Because the protein NDUFAF2 serves as a critical assembly factor for mitochondrial complex I, the investigators sought to determine whether NDUFAF2 deficiency contributes directly to fibroblast dysfunction and whether treatment with bezafibrate could ameliorate the associated pathological phenotypes.
The investigators utilized cultured L929 fibroblasts as an in vitro model. The research team generated a stable knockdown of the NDUFAF2 gene in these cells. This model allowed evaluation of the consequences of complex I assembly failure on cellular health and mitochondrial performance.
The stable knockdown of NDUFAF2 in L929 fibroblasts impaired cell viability, actively promoted cellular apoptosis, and caused marked mitochondrial dysfunction. However, subsequent treatment with bezafibrate partially rescued these abnormal cellular phenotypes. These in vitro findings demonstrated that bezafibrate partially rescued survival and mitochondrial abnormalities in the cells.
To determine whether the protective properties of bezafibrate extended beyond cell culture to an in vivo setting of pharmacological complex I inhibition, the researchers examined rotenone-treated mice. The researchers also examined rotenone-treated mice, a model of complex I inhibition, to test whether bezafibrate could mitigate disease symptoms in an intact organism.
Rotenone exposure successfully induced an experimental Leigh syndrome-like phenotype in the mice, which was characterized by systemic weight loss, decreased food and water intake, motor dysfunction, and significantly shortened overall survival. Therapeutic administration of bezafibrate significantly attenuated all of these pathological abnormalities, showing that the compound effectively mitigated physiological deteriorations and functional behavioral deficits provoked by chemical complex I inhibition in vivo.
Mechanistic analyses in brain tissue revealed that bezafibrate improved mitochondrial function in fibroblast-enriched clusters. The treatment also restored molecular features associated with mitochondrial complex I homeostasis and reshaped critical disease-associated pathways, particularly those governing neuroactive ligand-receptor interactions and receptor-mediated mitophagy. These changes demonstrated pathway-level remodeling within brain tissue following systemic administration.
Targeted validation supported the involvement of the MCHR1/CRHR2-cAMP axis and mitophagy-related remodeling in these therapeutic responses. The authors concluded that NDUFAF2-dependent mitochondrial homeostasis in fibroblasts represents an important and previously underappreciated contributor to Leigh syndrome-like pathology. Furthermore, they emphasized that bezafibrate possesses therapeutic potential in experimental models of complex I dysfunction, warranting future investigation in genetically defined disease models.
Subject of Research: Therapeutic evaluation of bezafibrate in cellular and animal models of mitochondrial complex I deficiency
Article Title: Bezafibrate partially rescues mitochondrial dysfunction in NDUFAF2-deficient cellular and rotenone-induced models of complex I impairment
Article References: Wang, D., Lai, P., Cheng, K., Yu, P., Jiang, X., Shen, T., Lou, W., & Li, X. (2026). Bezafibrate partially rescues mitochondrial dysfunction in NDUFAF2-deficient cellular and rotenone-induced models of complex I impairment. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04689-5
Image Credits: AI Generated
DOI: 10.1186/s13023-026-04689-5
Keywords: Bezafibrate, NDUFAF2, Mitochondrial complex I, Leigh syndrome, Mitochondrial encephalopathy, L929 fibroblasts, Rotenone, Oxidative phosphorylation, Mitochondrial dysfunction, Cell viability, Apoptosis, Motor dysfunction, Receptor-mediated mitophagy, MCHR1, CRHR2, cAMP axis, Bioenergetic failure
News Source: Ophelia Keating. (November 17, 2026). Bezafibrate Partially Rescues Mitochondrial Dysfunction in Cellular and Mouse Models. Scienmag.



